The compounds, where Cp' = C(5)H(5), a series, and C(5)H(4)Me, b series, are generated via treatment of with HB(C(6)F(5))(2). When allowed to undergo irreversible methane loss in the presence of an excess of the sterically modest alkynes 2-butyne or phenylacetylene, the putative intermediates 1a and 1b are trapped as the tantala-3-boratacyclopentene compounds 2 and 3, respectively. In these complexes, the alkyne and borataalkene ligands have reductively coupled at the d(2) tantalum center. For the unsymmetrical alkyne, a kinetic product resulting from coupling in the opposite regiochemical sense is observed; the thermodynamic products 3-t incorporate the phenyl group in the alpha position of the tantalaboratacyclic ring. Two of these compounds (2b and 3b-t) were characterized crystallographically. For bulkier alkynes (diphenylacetylene, 1-phenyl-1-propyne, and 3-hexyne), intermediates with similar spectroscopic properties to the tantala-3-boratacyclopentenes were observed, but the ultimate products were the vinylalkylidene compounds 5-(R,R'). Compound 5-(Ph,Me) was characterized crystallographically, and it was found that the vinylalkylidene binds to the metal in an eta(1)-bonding mode, with the tantalum center receiving further ligation through a hydridoborate moiety. Mechanistic studies suggest that these products arise via retrocyclization of the tantala-3-boratacyclopentenes formed kinetically. These studies represent the first studies concerning the reactivity of a borataalkene ligand at a transition metal center and show that it can behave in an "olefin-like" manner, despite having a more flexible array of bonding modes available to it than an olefin.
No takes yet. Share an insight, caveat, or question.
Cook et al. (2002) studied this question.
Synapse has enriched 4 closely related papers on similar clinical questions. Consider them for comparative context: